Walmart's "everyday low prices" should attract customers even if a recession comes. Which group of individuals is in the best ...

RBC Capital raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $420 from $408 and keeps a Sector Perform rating on the shares.

Vertex Pharmaceuticals (NasdaqGS:VRTX) saw a notable 20.53% share price increase over the last quarter, which coincided with several key developments in its Type 1 Diabetes (T1D) initiatives. The ...

We recently published a list of 20 Most Expensive Stocks Insiders Are Dumping In March. In this article, we are going to take ...

Looking ahead, Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is poised for continued growth, supported by recent FDA approvals, including ALYFTREK for CF patients and JOURNAVX for acute pain.

Consider that since December, Vertex Pharmaceuticals has earned approval for two brand-new medicines: Alyftrek and Journavx. The former is the biotech's latest cystic fibrosis (CF) medicine.

Detailed price information for Vertex Pharmaceutic (VRTX-Q) from The Globe and Mail including charting and trades.

“2024 marked a year of tremendous growth for Vertex and we anticipate 2025 will be another important year with the landmark JOURNAVX approval and launch for moderate-to-severe acute pain; the launch ...

On March 7, 2025, the company received approval from the UK’s Medicines and Healthcare products Regulatory Agency for ALYFTREK, a once-daily treatment for cystic fibrosis in patients aged six ...

While in the near term, expansion to younger age groups should continue to drive CF sales growth, the launch of Alyftrek should drive growth in the medium term. The approval of Vertex and partner ...

The drug, Alyftrek, works by regulating the flow of water and salt in and out of organs in CF patients, improving their overall function. It helps fix a faulty protein (CFTR) in their cells ...